Scorpion Venom Peptide Derivative Blocks Enterovirus 71 and Other Viruses at Early Infection Stages | Research

The takeaway

A modified scorpion venom peptide (BmKn2-T5) inhibited enterovirus 71 in a dose-dependent manner during early infection stages in vitro, with less cell toxicity than the parent peptide and additional activity against dengue, Zika, and herpes viruses.

4 viruses inhibited
BmKn2-T5 blocked not only EV71 but also dengue, Zika, and herpes simplex viruses at early infection stages

What the researchers found

BmKn2-T5 inhibited EV71 dose-dependently in vitro, acting at early stages of the viral cycle. It also suppressed DENV, ZIKV, and HSV-1 replication, suggesting a shared early-stage viral target.

Why it matters

There is no approved antiviral for EV71, which causes significant childhood illness and occasional deaths. A peptide that blocks early viral entry could be developed into a broad-spectrum antiviral, potentially covering multiple unrelated viruses.

The numbers in context

BmKn2-T5 inhibited EV71 when applied during early stages of infection in cell culture models.

How the study worked

In vitro antiviral testing of BmKn2 and 5 derivatives against EV71 in cell cultures. Time-of-drug-addition experiments identified the affected viral life cycle stage. Cytotoxicity assessed. Cross-tested against dengue, Zika, and HSV-1.

Who was studied

Cell cultures infected with enterovirus 71

What this study cannot tell us

In vitro study only — cell culture antiviral activity doesn't guarantee effectiveness in animals or humans. The exact molecular target on the viruses hasn't been identified. Stability, delivery, and safety in vivo are unknown.

How to read the evidence

Preliminary evidence from in vitro cell culture experiments only. No animal or human testing has been conducted.

When this study was published

Published in 2024; cutting-edge antiviral peptide research.

The bigger picture

Antiviral peptides from animal venoms are an emerging research frontier. Finding a single peptide that works against both enveloped and unenveloped viruses through early-stage inhibition could revolutionize broad-spectrum antiviral development, which currently relies mainly on small-molecule drugs with narrower targets.

Questions still open

What is the specific molecular target that BmKn2-T5 blocks during early viral entry?
Does BmKn2-T5 show antiviral activity in animal models of EV71 infection?
Could this peptide be developed as a topical or inhaled antiviral for pediatric use?

Common questions

What is enterovirus 71 and why is it dangerous?

EV71 is the main virus behind hand, foot, and mouth disease, which primarily affects young children. While usually mild, it can cause severe neurological complications including brain inflammation and paralysis, and can be fatal. It's especially common in Asia-Pacific countries and has no approved antiviral treatment.

How can one peptide work against such different viruses?

The researchers found that BmKn2-T5 blocks a very early step in infection that appears to be shared across these different viruses. While the exact target isn't yet identified, it likely involves a fundamental process that multiple viruses depend on to enter cells.

Read the original research

Scorpion Venom Antimicrobial Peptide Derivative BmKn2-T5 Inhibits Enterovirus 71 in the Early Stages of the Viral Life Cycle In Vitro.

Biomolecules, 14(5)

View on PubMed ↗Publisher’s paper ↗

Citation

Xia, Zhiqiang; Wang, Huijuan; Chen, Weilie; Wang, Aili; Cao, Zhijian. (2024). Scorpion Venom Antimicrobial Peptide Derivative BmKn2-T5 Inhibits Enterovirus 71 in the Early Stages of the Viral Life Cycle In Vitro.. Biomolecules, 14(5). https://doi.org/10.3390/biom14050545